United States securities and exchange commission logo February 23, 2022 Brian O Callaghan Chief Executive Officer and Director ObsEva SA Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland Re: ObsEva SA Registration Statement on Form F-3 Filed February 17, 2022 File No. 333-262820 Dear Mr. O Callaghan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Davis at 202-551-4385 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan Sansom, Esq.